Cutia Therapeutics (HKG:2487)
Hong Kong · Delayed Price · Currency is HKD 1.950
-0.050 (-2.50%)
Aug 27, 2026, 4:08 PM HKT
Cutia Therapeutics Revenue
In the year 2025, Cutia Therapeutics had annual revenue of 336.15M CNY with 20.22% growth. Cutia Therapeutics had revenue of 269.86M in the half year ending December 31, 2025, with 161.29% growth.
Revenue
336.15M CNY
Revenue Growth
+20.22%
P/S Ratio
1.94
Revenue / Employee
1.11M CNY
Employees
304
Market Cap
726.74M HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 336.15M | 56.54M | 20.22% |
| Dec 31, 2024 | 279.62M | 141.99M | 103.17% |
| Dec 31, 2023 | 137.62M | 126.26M | 1,110.83% |
| Dec 31, 2022 | 11.37M | 9.33M | 457.70% |
| Dec 31, 2021 | 2.04M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| 3D Medicines | 396.26M |
| JW (Cayman) Therapeutics Co. | 315.65M |
| Wuhan YZY Biopharma | 74.40M |
| Brii Biosciences | 66.16M |
| CANbridge Pharmaceuticals | 55.62M |
| Shanghai Bio-heart Biological Technology | 50.00M |
| Kintor Pharmaceutical | 36.37M |
| Transcenta Holding | 8.27M |